Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells

5 Dec 2012

Abstract excerpt

Activation of Wnt signalling due to inability to degrade β-catenin is found in >85% of colorectal cancers. Approximately half of colon cancers express a constitutively active KRAS protein. A significant fraction of patients show both abnormalities. We previously reported that simultaneous down-regulation of both β-catenin and KRAS was necessary to induce significant cell death and tumor growth inhibition of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Peptidase Inhibition and Analysis
Share to Wnt/β-catenin signaling in development and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23227266
DOI: 10.1371/journal.pone.0051449

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer CellsPMID 23227266Read ↗

WNT Signalling Promotes NF-κB Activation and Drug Resistance in KRAS-Mutant Colorectal CancerSemantic proximity Read ↗

The potential of targeting Wnt/β-catenin in colon cancerSemantic proximity Read ↗

Small Molecule Destabilizer of β-Catenin and Ras Proteins Antagonizes Growth of K-Ras Mutation-Driven Colorectal Cancers Resistant to EGFR Inhibitors.Semantic proximity Read ↗

WNT signalling promotes NF-κB activation and drug resistance in KRAS-mutant colorectal cancer.Semantic proximity Read ↗

Wnt signaling as a therapeutic target for cancer.Semantic proximity Read ↗

Targeting the Wnt/β-catenin signal pathway for the treatment of gastrointestinal cancer: Potential for advancementSemantic proximity Read ↗

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.Semantic proximity Read ↗

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.Semantic proximity Read ↗

Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models.Semantic proximity Read ↗

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximabSemantic proximity Read ↗

Simultaneous destabilization of β-catenin and Ras via targeting of the axin-RGS domain as a potential therapeutic strategy for colorectal cancer.Semantic proximity Read ↗

CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.